4//SEC Filing
Insys Therapeutics, Inc. 4
Accession 0001209191-15-011381
CIK 0001516479operating
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 4:30 PM ET
Size
21.4 KB
Accession
0001209191-15-011381
Insider Transaction Report
Form 4
BAKER DARRYL S
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2015-02-06$7.26/sh+6,248$45,360→ 40,625 total - Sale
Common Stock
2015-02-06$52.25/sh−6,248$326,470→ 19,377 total - Exercise/Conversion
Common Stock
2015-02-06$2.36/sh+15,000$35,400→ 34,377 total - Sale
Common Stock
2015-02-06$52.25/sh−15,000$783,780→ 25,625 total - Sale
Common Stock
2015-02-09$52.18/sh−8,752$456,714→ 19,377 total - Exercise/Conversion
Stock Option (right to buy)
2015-02-06−6,248→ 118,752 totalExercise: $7.26Exp: 2023-05-13→ Common Stock (6,248 underlying) - Exercise/Conversion
Common Stock
2015-02-09$7.26/sh+8,752$63,540→ 28,129 total - Exercise/Conversion
Stock Option (right to buy)
2015-02-06−15,000→ 60,000 totalExercise: $2.36Exp: 2022-12-26→ Common Stock (15,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2015-02-09−8,752→ 110,000 totalExercise: $7.26Exp: 2023-05-13→ Common Stock (8,752 underlying)
Footnotes (9)
- [F1]The exercise price reflects a 3-for-2 stock split effected by the Issuer on March 28, 2014.
- [F2]On March 28, 2014, the Issuer effected a 3-for-2 stock split, resulting in the reporting person's ownership of 10,000 additional shares of common stock.
- [F3]Includes 4,127 shares and 563 shares, respectively, acquired pursuant to the Issuer's ESPP on June 11, 2014 and December 11, 2014, respectively.
- [F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.0000 to $52.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.0000 to $52.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The option vests in 36 equal monthly installments measured from the grant date of December 27, 2012 and will be fully vested and exercisable on December 27, 2015.
- [F8]On March 28, 2014, the Issuer effected a 3-for-2 stock split, resulting in the reporting person's ownership of 35,000 additonal options.
- [F9]The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 14, 2017.
Documents
Issuer
Insys Therapeutics, Inc.
CIK 0001516479
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001516479
Filing Metadata
- Form type
- 4
- Filed
- Feb 9, 7:00 PM ET
- Accepted
- Feb 10, 4:30 PM ET
- Size
- 21.4 KB